MedTrace Logo

The Efficacy of Claritin in Healthy Subjects

NCT01451996 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2018-03-13

Study results available
· View outcomes & findings →

Summary

The primary goal of this study is to examine determinants of the efficacy of Claritin.

Conditions

  • Healthy

Interventions

DRUG

Claritin

Subject will be given 10mg Claritin tablet.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Anup Malani, J.D., Ph.D · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01451996 on ClinicalTrials.gov